$OCUL
OCULAR THERAPEUTIX, INC

2024 Q3 Form 10-Q Financial Statement

#000155837024011202 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $15.43M $16.44M
YoY Change 2.28% 8.26%
Cost Of Revenue $1.561M $1.509M
YoY Change 13.36% 15.72%
Gross Profit $13.86M $14.93M
YoY Change 1.17% 7.56%
Gross Profit Margin 89.88% 90.82%
Selling, General & Admin $22.81M $29.67M
YoY Change 27.43% 53.24%
% of Gross Profit 164.51% 198.67%
Research & Development $37.05M $28.86M
YoY Change 146.71% 91.18%
% of Gross Profit 267.27% 193.26%
Depreciation & Amortization $959.0K $956.0K
YoY Change 7.75% 46.63%
% of Gross Profit 6.92% 6.4%
Operating Expenses $59.86M $58.52M
YoY Change 81.85% 69.87%
Operating Profit -$46.00M -$43.59M
YoY Change 139.4% 111.91%
Interest Expense $9.505M -$187.0K
YoY Change 177.44% 66.96%
% of Operating Profit
Other Income/Expense, Net $9.505M -$187.0K
YoY Change -49.17%
Pretax Income -$36.49M -$43.84M
YoY Change 6917.88% 111.97%
Income Tax
% Of Pretax Income
Net Earnings -$36.49M -$43.78M
YoY Change 6972.29% 111.67%
Net Earnings / Revenue -236.58% -266.27%
Basic Earnings Per Share -$0.22 -$0.26
Diluted Earnings Per Share -$0.22 -$0.26
COMMON SHARES
Basic Shares Outstanding 155.9M 154.9M
Diluted Shares Outstanding 167.0M 165.8M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $427.2M $459.7M
YoY Change 286.27% 590.16%
Cash & Equivalents $427.2M $459.7M
Short-Term Investments
Other Short-Term Assets $13.15M $6.116M
YoY Change 168.39% 33.16%
Inventory $2.405M $2.547M
Prepaid Expenses
Receivables $30.24M $30.23M
Other Receivables $0.00 $0.00
Total Short-Term Assets $473.0M $498.6M
YoY Change 234.86% 395.06%
LONG-TERM ASSETS
Property, Plant & Equipment $10.05M $10.89M
YoY Change -19.56% -45.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.614M $1.614M
YoY Change -10.33% -8.5%
Total Long-Term Assets $17.36M $18.51M
YoY Change -17.84% -15.29%
TOTAL ASSETS
Total Short-Term Assets $473.0M $498.6M
Total Long-Term Assets $17.36M $18.51M
Total Assets $490.4M $517.1M
YoY Change 201.98% 321.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.001M $3.689M
YoY Change 0.43% 3.28%
Accrued Expenses $30.45M $24.36M
YoY Change 5.41% -7.42%
Deferred Revenue $190.0K $269.0K
YoY Change -40.06% -31.2%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.36M $29.97M
YoY Change 3.69% -7.37%
LONG-TERM LIABILITIES
Long-Term Debt $67.82M $67.13M
YoY Change -8.23% 25.99%
Other Long-Term Liabilities $117.0K $114.0K
YoY Change 10.38% -99.66%
Total Long-Term Liabilities $117.0K $114.0K
YoY Change 10.38% -99.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.36M $29.97M
Total Long-Term Liabilities $117.0K $114.0K
Total Liabilities $138.3M $139.4M
YoY Change -10.47% 16.68%
SHAREHOLDERS EQUITY
Retained Earnings -$842.7M -$806.2M
YoY Change 26.08% 20.72%
Common Stock $1.195B $1.184B
YoY Change 76.68% 76.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $352.0M $377.7M
YoY Change
Total Liabilities & Shareholders Equity $490.4M $517.1M
YoY Change 201.98% 321.92%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$36.49M -$43.78M
YoY Change 6972.29% 111.67%
Depreciation, Depletion And Amortization $959.0K $956.0K
YoY Change 7.75% 46.63%
Cash From Operating Activities -$36.56M -$24.80M
YoY Change 372.95% 23.55%
INVESTING ACTIVITIES
Capital Expenditures $89.00K $742.0K
YoY Change -65.77% -62.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$89.00K -$742.0K
YoY Change -65.77% -62.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.178M 2.196M
YoY Change -91.96% -77.23%
NET CHANGE
Cash From Operating Activities -36.56M -24.80M
Cash From Investing Activities -89.00K -742.0K
Cash From Financing Activities 4.178M 2.196M
Net Change In Cash -32.47M -23.35M
YoY Change -173.88% 87.99%
FREE CASH FLOW
Cash From Operating Activities -$36.56M -$24.80M
Capital Expenditures $89.00K $742.0K
Free Cash Flow -$36.65M -$25.54M
YoY Change 358.67% 15.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
155624363
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114963193
CY2024Q2 us-gaap Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration
RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
195807000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30232000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26179000
CY2024Q2 us-gaap Inventory Net
InventoryNet
2547000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2305000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
150000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6116000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7794000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
498585000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
232235000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11739000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1614000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1614000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6005000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6472000
CY2024Q2 us-gaap Assets
Assets
517091000
CY2023Q4 us-gaap Assets
Assets
252060000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3689000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
269000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
255000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1656000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1586000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29972000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34896000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6100000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6878000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22078000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
15 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
155921685
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
459690000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
195807000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30232000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26179000
CY2024Q2 us-gaap Inventory Net
InventoryNet
2547000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2305000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
150000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6116000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7794000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
498585000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
232235000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11739000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1614000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1614000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6005000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6472000
CY2024Q2 us-gaap Assets
Assets
517091000
CY2023Q4 us-gaap Assets
Assets
252060000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3689000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4389000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24358000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28666000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
269000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
255000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1656000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1586000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29972000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34896000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6100000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6878000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22078000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
29987000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14000000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14135000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
67132000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
65787000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
114000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
108000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
9138000
CY2024Q2 us-gaap Liabilities
Liabilities
139396000
CY2023Q4 us-gaap Liabilities
Liabilities
160929000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
155624363
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114963193
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1183882000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
788697000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-806203000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-697578000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
377695000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91131000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
517091000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252060000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16441000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15186000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31215000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28561000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1509000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1304000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2835000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2517000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28857000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
29987000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14000000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14135000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
67132000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
65787000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
114000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
108000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
9138000
CY2024Q2 us-gaap Liabilities
Liabilities
139396000
CY2023Q4 us-gaap Liabilities
Liabilities
160929000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
155624363
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114963193
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1183882000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
788697000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-806203000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-697578000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
377695000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91131000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
517091000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252060000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16441000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15186000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28561000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1509000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1304000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2835000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2517000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28857000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15094000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49592000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29842000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9994000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11153000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20177000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21989000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19671000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15094000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49592000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29842000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9994000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11153000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20177000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21989000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19671000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8205000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33818000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17332000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
60031000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
35756000
us-gaap Costs And Expenses
CostsAndExpenses
106422000
us-gaap Costs And Expenses
CostsAndExpenses
71680000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43590000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20570000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75207000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43119000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
6036000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
748000
us-gaap Investment Income Net
InvestmentIncomeNet
9958000
us-gaap Investment Income Net
InvestmentIncomeNet
1312000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3196000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7247000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3760000
CY2024Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-3027000
CY2023Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1131000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-8179000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-27950000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-187000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33418000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7881000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-43777000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20682000
us-gaap Net Income Loss
NetIncomeLoss
-108625000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165824778
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78047705
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148922937
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77718823
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8205000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33818000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17332000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
60031000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
35756000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43590000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20570000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75207000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43119000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
6036000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
748000
us-gaap Investment Income Net
InvestmentIncomeNet
9958000
us-gaap Investment Income Net
InvestmentIncomeNet
1312000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3196000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1991000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7247000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3760000
CY2024Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-3027000
CY2023Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1131000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-8179000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-27950000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-187000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33418000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20682000
us-gaap Net Income Loss
NetIncomeLoss
-108625000
us-gaap Net Income Loss
NetIncomeLoss
-51000000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165824778
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78047705
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148922937
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77718823
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
165824778
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78047705
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148922937
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77718823
us-gaap Profit Loss
ProfitLoss
-108625000
us-gaap Profit Loss
ProfitLoss
-51000000
us-gaap Share Based Compensation
ShareBasedCompensation
19271000
us-gaap Share Based Compensation
ShareBasedCompensation
8985000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
165824778
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78047705
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148922937
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77718823
us-gaap Profit Loss
ProfitLoss
-108625000
us-gaap Profit Loss
ProfitLoss
-51000000
us-gaap Share Based Compensation
ShareBasedCompensation
19271000
us-gaap Share Based Compensation
ShareBasedCompensation
8985000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2537000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2481000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-8179000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1876000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1135000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-27950000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4053000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5984000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1678000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
565000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
242000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
230000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-727000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-320000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-467000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-790000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6171000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-578000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-121000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
682000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-708000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-875000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58689000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40048000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5369000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5369000
ocul Proceeds From Issuance Of Protective Advance
ProceedsFromIssuanceOfProtectiveAdvance
2000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6574000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
481000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
492000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
418000
ocul Repayment Of Protective Advance
RepaymentOfProtectiveAdvance
2000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
316353000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8824000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
323419000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9723000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
263733000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35694000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197571000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104064000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2537000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2481000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-8179000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1876000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1135000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-27950000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4053000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5984000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1678000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
242000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
230000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-727000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-320000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-467000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-790000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6171000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-578000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
682000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58689000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40048000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
997000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5369000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-997000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5369000
ocul Proceeds From Issuance Of Protective Advance
ProceedsFromIssuanceOfProtectiveAdvance
2000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6574000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
481000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
492000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
418000
ocul Repayment Of Protective Advance
RepaymentOfProtectiveAdvance
2000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
316353000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8824000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
323419000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9723000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35694000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104064000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68370000
us-gaap Interest Paid Net
InterestPaidNet
1521000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
43000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
116000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91131000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4870000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
316353000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
52499000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7978000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-64848000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
407983000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1704000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461304000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68370000
us-gaap Interest Paid Net
InterestPaidNet
15595000
us-gaap Interest Paid Net
InterestPaidNet
1521000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
43000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
116000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91131000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4870000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
316353000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
52499000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7978000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-64848000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
407983000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1704000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
492000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11293000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-43777000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
377695000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3087000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-806203000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
459690000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:14pt 0pt 0pt 0pt;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the measurement and recognition of reserves for variable consideration related to product sales, revenue recognition related to a collaboration agreement that contains multiple promises, the fair value of derivatives, stock-based compensation, and realizability of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</p>
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
492000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11293000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-43777000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9711000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
403000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
418000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8824000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4413000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20682000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3087000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-806203000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
459690000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:14pt 0pt 0pt 0pt;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the measurement and recognition of reserves for variable consideration related to product sales, revenue recognition related to a collaboration agreement that contains multiple promises, the fair value of derivatives, stock-based compensation, and realizability of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</p>
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14390000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
121000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14269000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14390000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
121000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14269000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
459690000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66606000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1614000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461304000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68370000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
459690000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66606000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1614000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68370000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
267000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
302000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1057000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1012000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1223000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
991000
CY2024Q2 us-gaap Inventory Net
InventoryNet
2547000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2305000
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
37
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.13
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
1601000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
395000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
1206000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
267000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
302000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1057000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1012000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1223000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
991000
CY2024Q2 us-gaap Inventory Net
InventoryNet
2547000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2305000
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
37
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.13
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
1601000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
395000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
1206000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8435000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8156000
CY2024Q2 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
5655000
CY2023Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
5117000
CY2024Q2 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4621000
CY2023Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1488000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1918000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1525000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1748000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8435000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8156000
CY2024Q2 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
5655000
CY2023Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
5117000
CY2024Q2 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4621000
CY2023Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1488000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1918000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1525000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1748000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
1206000
CY2024Q2 ocul Accrued Interest Notes Payable
AccruedInterestNotesPayable
775000
CY2023Q4 ocul Accrued Interest Notes Payable
AccruedInterestNotesPayable
803000
CY2023Q4 ocul Accrued Interest Convertible Notes
AccruedInterestConvertibleNotes
10886000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24358000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28666000
CY2024Q2 ocul Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2024Q2 ocul Royalty Fee Obligation
RoyaltyFeeObligation
-573000
ocul Royalty Fee Obligation
RoyaltyFeeObligation
-1088000
CY2024Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-3027000
CY2023Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1131000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-8179000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
691000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
1206000
CY2024Q2 ocul Accrued Interest Notes Payable
AccruedInterestNotesPayable
775000
CY2023Q4 ocul Accrued Interest Notes Payable
AccruedInterestNotesPayable
803000
CY2023Q4 ocul Accrued Interest Convertible Notes
AccruedInterestConvertibleNotes
10886000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24358000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28666000
CY2024Q2 ocul Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2024Q2 ocul Royalty Fee Obligation
RoyaltyFeeObligation
-573000
ocul Royalty Fee Obligation
RoyaltyFeeObligation
-1088000
CY2024Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-3027000
CY2023Q2 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1131000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-5432000
CY2024Q2 ocul Increased Common Stock Shares Authorized
IncreasedCommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 ocul Number Of Stock Based Compensation Plans
NumberOfStockBasedCompensationPlans
3
CY2024Q2 ocul Number Of Stock Based Compensation Plans
NumberOfStockBasedCompensationPlans
3
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
731580
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1040261
CY2024Q2 ocul Increased Common Stock Shares Authorized
IncreasedCommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 ocul Number Of Stock Based Compensation Plans
NumberOfStockBasedCompensationPlans
3
CY2024Q2 ocul Number Of Stock Based Compensation Plans
NumberOfStockBasedCompensationPlans
3
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
731580
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1040261
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11293000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4413000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19271000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8985000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
5092000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
7493000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
43728000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8985000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
5092000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
7493000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
43728000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Net Income Loss
NetIncomeLoss
-108625000
us-gaap Net Income Loss
NetIncomeLoss
-51000000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165824778
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78047705
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148922937
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77718823
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2023Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2024Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-43777000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20682000
us-gaap Net Income Loss
NetIncomeLoss
-108625000
us-gaap Net Income Loss
NetIncomeLoss
-51000000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165824778
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78047705
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148922937
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77718823
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2023Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2024Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23579285
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23757619
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23579285
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23757619
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23579285
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23757619
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23579285
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23757619
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011202-index-headers.html Edgar Link pending
0001558370-24-011202-index.html Edgar Link pending
0001558370-24-011202.txt Edgar Link pending
0001558370-24-011202-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20240630.xsd Edgar Link pending
ocul-20240630x10q.htm Edgar Link pending
ocul-20240630xex10d3.htm Edgar Link pending
ocul-20240630xex10d4.htm Edgar Link pending
ocul-20240630xex10d5.htm Edgar Link pending
ocul-20240630xex10d5001.jpg Edgar Link pending
ocul-20240630xex10d5002.jpg Edgar Link pending
ocul-20240630xex10d6.htm Edgar Link pending
ocul-20240630xex31d1.htm Edgar Link pending
ocul-20240630xex31d2.htm Edgar Link pending
ocul-20240630xex32d1.htm Edgar Link pending
ocul-20240630xex32d2.htm Edgar Link pending
ocul-20240630xex3d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
ocul-20240630_def.xml Edgar Link unprocessable
ocul-20240630_lab.xml Edgar Link unprocessable
ocul-20240630_pre.xml Edgar Link unprocessable
ocul-20240630x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocul-20240630_cal.xml Edgar Link unprocessable